IP Library › Granted Patent US 12,465,615
Granted Patent B2
US 12,465,615 · App. 17/705,060 · Granted Nov 11, 2025

Aqueous solutions containing purines and pyrimidines and uses thereof

Inventors: Paul Glidden (Emeryville, CA); Eric Scharin (Emeryville, CA)
Assignee: UCB BIOSCIENCES, INC.
A61K31/708A61K31/7068A61K31/7072A61K31/7076
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,465,615
App. No.
17/705,060
Granted
Nov 11, 2025
Kind
B2
Abstract

Provided are compositions comprising a first heteroaryl compound and a second heteroaryl compound dissolved in an aqueous liquid. Also provided are methods of treating a patient that include orally administering such an aqueous liquid to a patient, for example, wherein the patient has been diagnosed with a mitochondrial depletion syndrome. Kits are provided that include the first heteroaryl compound, the second heteroaryl compound, and optionally instructions for dissolving the first heteroaryl compound and the second heteroaryl compound in an aqueous liquid and administering the solution to a patient.

Claims (59)

1 . A composition comprising a first heteroaryl compound and a second heteroaryl compound dissolved in an aqueous liquid, wherein the solubility of the first heteroaryl compound in the aqueous liquid is higher by 10 mg/mL or more compared with an otherwise identical aqueous liquid that lacks the second heteroaryl compound, and

wherein the first heteroaryl compound is Compound G

and the second heteroaryl compound is Compound A,

or the first heteroaryl compound is deoxythymidine and the second heteroaryl compound is deoxycytidine;

wherein if the first heteroaryl compound is Compound G

and the second heteroaryl compound is Compound A,

then a concentration of Compound A is about 30 mg/mL or more and a concentration of Compound G is about 60 mg/mL or more; and

wherein if the first heteroaryl compound is deoxythymidine and the second heteroaryl compound is deoxycytidine, then a concentration of deoxycytidine is about 50 mg/mL or more, and a concentration of deoxythymidine is about 60 mg/mL or more.

2 . The composition of claim 1 , wherein the first heteroaryl compound is deoxythymidine and the second heteroaryl compound is deoxycytidine.

3 . The composition of claim 2 , wherein the deoxythymidine is at a concentration of about 70 mg/mL to about 100 mg/mL; and wherein the deoxycytidine is at a concentration of about 60 mg/mL to about 100 mg/mL.

4 . The composition of claim 3 , wherein the mass of deoxythymidine ranges from 0.5 g to 6.0 g per dose unit; and wherein the mass of deoxycytidine ranges from 0.5 g to 6.0 g per dose unit.

5 . The composition of claim 1 , wherein the combined mass of deoxythymidine and deoxycytidine ranges from 1.0 g to 12.0 g per dose unit.

6 . The composition of claim 1 , wherein the first heteroaryl compound is Compound G

and the second heteroaryl compound is Compound A

7 . The composition of claim 6 , wherein Compound G is at a concentration of about 70 mg/mL or more.

8 . The composition of claim 6 , wherein Compound A is at a concentration ranging from about 40 mg/mL to about 100 mg/mL.

9 . The composition of claim 6 , wherein the molar ratio of Compound G to Compound A is from about 1:0.1 to about 1:1.

10 . The composition of claim 6 , wherein the mass of Compound G ranges from 0.5 g to 6.0 g per dose unit, and wherein the mass of Compound A ranges from 0.5 g to 5.0 g per dose unit.

11 . The composition of claim 6 , wherein the combined mass of Compound G and Compound A ranges from 1.0 g to 12.0 g per dose unit.

12 . The composition of claim 1 , wherein if the first heteroaryl compound is deoxythymidine and the second heteroaryl compound is deoxycytidine, then the deoxycytidine is at a concentration of 70 mg/ml or more, and the deoxythymidine is at a concentration of about 70 mg/mL or more.

13 . The composition of claim 1 , wherein if the first heteroaryl compound is deoxythymidine and the second heteroaryl compound is deoxycytidine, then the deoxycytidine is at a concentration of 90 mg/ml or more, and the deoxythymidine is at a concentration of about 90 mg/mL or more.

14 . The composition of claim 1 , wherein if the first heteroaryl compound is Compound G and the second heteroaryl compound is Compound A; then the Compound A is at a concentration of 70 mg/ml or more, and the Compound G is at a concentration of about 70 mg/mL or more.

15 . The composition of claim 1 , wherein if the first heteroaryl compound is Compound G and the second heteroaryl compound is Compound A; then the Compound A is at a concentration of 90 mg/ml or more, and the Compound G is at a concentration of about 90 mg/mL or more.

16 . The composition of claim 1 , wherein the volume of aqueous liquid is from 1 mL to 150 mL.

17 . A method comprising dissolving a first heteroaryl compound and a second heteroaryl compound in an aqueous liquid to form a composition, wherein the solubility of the first heteroaryl compound in the aqueous liquid is higher by 10 mg/mL or more compared to an otherwise identical composition comprising the first heteroaryl compound dissolved in an aqueous liquid without the second heteroaryl compound, and

i. wherein the first heteroaryl compound is Compound G

and the second heteroaryl compound is Compound A,

or the first heteroaryl compound is deoxythymidine and the second heteroaryl compound is deoxycytidine;

wherein if the first heteroaryl compound is Compound G and the second heteroaryl compound is Compound A, then a concentration of Compound A in the composition is about 30 mg/mL or more and a concentration of Compound G in the composition is about 60 mg/mL or more; and

wherein if the first heteroaryl compound is deoxythymidine and the second heteroaryl compound is deoxycytidine, then a concentration of deoxycytidine in the composition is about 50 mg/mL or more, and a concentration of deoxythymidine in the composition is about 60 mg/mL or more;

ii. wherein the dissolving is performed for about 5 minutes or less and at least 95% of the first heteroaryl compound and at least 95% of the second heteroaryl compound are dissolved.

18 . The method of claim 17 , wherein the first heteroaryl compound is deoxythymidine and the second heteroaryl compound is deoxycytidine.

19 . The method of claim 18 , wherein the deoxythymidine is present at a concentration ranging from about 60 mg/mL to about 90 mg/mL.

20 . The method of claim 18 , wherein the mass of deoxythymidine ranges from about 0.5 g to about 6.0 g per dose unit, and wherein the mass of deoxycytidine ranges from 0.5 g to 6.0 g per dose unit.

21 . The method of claim 18 , wherein the deoxycytidine is present at a concentration ranging from about 50 mg/mL to about 90 mg/mL.

22 . The method of claim 17 , wherein the combined mass of deoxythymidine and deoxycytidine ranges from 1.0 g to 12.0 g per dose unit.

23 . The method of claim 17 , wherein the first heteroaryl compound is Compound G

and the second heteroaryl compound is Compound A

24 . The method of claim 23 , wherein Compound G is present at a concentration ranging from about 60 mg/mL to about 100 mg/mL.

25 . The method of claim 23 , wherein Compound A is present at a concentration ranging from about 30 mg/mL to about 100 mg/mL.

26 . The method of claim 23 , wherein the mass of Compound G ranges from about 0.5 g to about 6.0 g per dose unit, and wherein the mass of Compound A ranges from 0.5 g to 6.0 g per dose unit.

27 . The method of claim 23 , wherein the combined mass of Compound G and Compound A ranges from 1.0 g to 12.0 g per dose unit.

28 . The method of claim 23 , wherein the molar ratio of Compound G to Compound A is from about 1:0.1 to about 1:1.

29 . The method of claim 17 , wherein the aqueous liquid is located inside a container comprising a mark corresponding to a specific volume of aqueous liquid recommended for dissolving the composition, wherein the mark corresponds to the specific volume of 40 mL, 50 mL, 80 mL, 100 mL, 120 mL, or 150 mL.

30 . The method of claim 17 , further comprising orally administering the solution to a subject, wherein the subject has a mitochondrial DNA depletion syndrome, a deficiency in deoxythymidine, a deficiency in deoxycytidine, a deficiency in deoxyguanosine, a deficiency in deoxyadenosine, a mutation in the TK2 gene, or a combination thereof.

31 . A kit, comprising:

a composition comprising a first heteroaryl compound and a second heteroaryl compound, wherein the solubility of the first heteroaryl compound in an aqueous liquid is higher by 10 mg/mL or more compared with an otherwise identical aqueous liquid that lacks the second heteroaryl compound;

wherein the first heteroaryl compound is Compound G

and the second heteroaryl compound is Compound A,

or the first heteroaryl compound is deoxythymidine and the second heteroaryl compound is deoxycytidine;

wherein the kit further comprises instructions, wherein the instructions direct the user to dissolve the second heteroaryl compound and the first heteroaryl compound in a specific volume of aqueous liquid;

wherein if the first heteroaryl compound is Compound G

and the second heteroaryl compound is Compound A,

then a specific volume is selected so that a concentration of Compound A is achieved of about 30 mg/mL or more and a concentration of Compound G is achieved of about 60 mg/mL or more;

wherein if the first heteroaryl compound is deoxythymidine and the second heteroaryl compound is deoxycytidine, then a specific volume is selected so that a concentration of deoxycytidine is achieved of about 50 mg/mL or more and a concentration of deoxythymidine achieved of about 60 mg/mL or more.

32 . The kit of claim 31 , further comprising a container with a lid and comprising at least one mark corresponding to a specific volume of aqueous liquid recommended for dissolving the composition, wherein the at least one mark corresponds to the specific volume of 40 mL, 50 mL, 80 mL, 100 mL, 120 mL, or 150 mL.

33 . The kit of claim 31 , wherein the first heteroaryl compound is deoxythymidine and the second heteroaryl compound is deoxycytidine.

34 . The kit of claim 31 , wherein the first heteroaryl compound is Compound G

and the second heteroaryl compound is Compound A

Assignments (3)
ASSIGNMENT OF ASSIGNOR’S INTEREST RESUBMISSION - ID: 508557651 Recorded Jul 12, 2024
From: ZOGENIX, INC.
To: UCB BIOSCIENCES, INC.
Reel/Frame 068311/0739 →
CHANGE OF NAME Recorded Dec 25, 2023
From: ZOGENIX MDS, INC.
To: ZOGENIX, INC.
Reel/Frame 065949/0270 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 17, 2022
From: GLIDDEN, PAUL; SCHARIN, ERIC
To: ZOGENIX MDS, INC.
Reel/Frame 060836/0578 →
Continuity (2)
Provisional Application 63166860 · Mar 26, 2021
Related Publication 20220305041A1 · Sep 29, 2022
References Cited (47)
US 6258795B1 · Von Borstel et al. · 2001 [cited by applicant]
US 10471087B2 · Hirano et al. · 2019 [cited by applicant]
US 11628182B2 · DiPietro · 2023 [cited by examiner]
US 11649259B2 · Glidden · 2023 [cited by examiner]
US 20110229871A1 · Ericson · 2011 [cited by applicant]
US 20160279159A1 · Hirano et al. · 2016 [cited by applicant]
US 20180161332A1 · Mart Seves et al. · 2018 [cited by applicant]
US 20210054014A1 · Glidden · 2021 [cited by applicant]
US 20210077519A1 · DiPietro · 2021 [cited by applicant]
US 20230000890A1 · DiPietro · 2023 [cited by examiner]
US 20240016938A1 · Mittur · 2024 [cited by examiner]
CN 202666004U · 2013 [cited by examiner]
WO WO2016205671A1 · 2016 [cited by applicant]
WO WO2019200340A1 · 2019 [cited by examiner]
WO WO2019204593A1 · 2019 [cited by applicant]
Wilson, D. S.; Keefe, A. D.; Random Mutagenesis by PCR, 2000, Current Protocols in Molecular Biology, pp. 8.3.1-8.3.9. (Year: 2000). [cited by examiner]
Pillwein, K.; et al. “Effect of Ischemia on Nucleosides and Bases in Rat Liver and Hepatoma 3924A” 1987, Cancer Research, vol. 47, pp. 3092-3096. (Year: 1987). [cited by examiner]
Mathew, J.; et al. “Physiology, Blood Plasma” 2023, StatPearls Publishing—NCBI Bookshelf 2023, PMID: 30285399. (Year: 2023). [cited by examiner]
Lopez-Gomez, C.; et al. “Bioavailability and cytosolic kinases modulate response to deoxynucleoside therapy in TK2 deficiency” 2019, EBioMedicine, vol. 46, pp. 356-367. (Year: 2019). [cited by examiner]
Gorbunova, V.; et al. “Rodents for comparative aging studies: from mice to beavers” 2008, Age, vol. 30, pp. 111-119. (Year: 2008). [cited by examiner]
Bulst, S.; et al. “In vitro supplementation with dAMP/dGMP leads to partial restoration of mtDNA levels in mitochondrial depletion syndromes” 2009, Human Molecular Genetics, vol. 18, pp. 1590-1599. (Year: 2009). [cited by examiner]
English translation of CN202666004U (translated on Jan. 22, 2024). (Year: 2013). [cited by examiner]
Definition of “solubility”, Merriam Webster (accessed Sep. 19, 2024). (Year: 2024). [cited by examiner]
International Search Report and Written Opinion for International Application No. PCT/US22/22015, International Searching Authority, United States, mailed on Aug. 2, 2022, 17 pages. [cited by applicant]
PubChem, “Thymidine,” CID 5789, pp. 1-7, accessed at https://pubchem.ncbi.nlm.nih.gov/compound/Thymidine, Sep. 16, 2004, 51 pages. [cited by applicant]
Behin, A., et al., “Adult Cases of Mitochondrial DNA Depletion Due to TK2 Defect: An Expanding Spectrum,” [cited by applicant]
Bourdon, A., et al., “Mutation of RRM2B, Encoding P53-Controlled Ribonucleotide Reductase (P53R2), Causes Severe Mitochondrial DNA Depletion,” [cited by applicant]
Copeland, W.C., “Inherited Mitochondrial Diseases of DNA Replication,” [cited by applicant]
Elpeleg, O., et al., “Deficiency of the ADP-Forming Succinyl-CoA Synthase Activity is Associated With Encephalomyopathy and Mitochondrial DNA Depletion,” [cited by applicant]
Garone, C., et al., “MPV17 Mutations Causing Adult-Onset Multisystemic Disorder With Multiple Mitochondrial DNA Deletions,” [cited by applicant]
Goethem, G.V., et al., “Mutation of POLG is Associated With Progressive External Ophthalmoplegia Characterized by mtDNA Deletions,” [cited by applicant]
Hirano, M., et al., “Defects of Intergenomic Communication: Autosomal Disorders That Cause Multiple Deletions and Depletion of Mitochondrial DNA,” [cited by applicant]
Kondo, D.G., et al., “Open-Label Uridine for Treatment of Depressed Adolescents With Bipolar Disorder,” [cited by applicant]
Longley, M.J., et al., “Mutant POLG2 Disrupts DNA Polymerase Gamma Subunits and Causes Progressive External Ophthalmoplegia,” [cited by applicant]
Mandel, H., et al., “The Deoxyguanosine Kinase Gene is Mutated in Individuals With Depleted Hepatocerebral Mitochondrial DNA,” [cited by applicant]
Naviaux, R.K. and Nguyen, K.V., “POLG Mutations Associated With Alpers' Syndrome and Mitochondrial DNA Depletion,” [cited by applicant]
Nishino, I., et al., “Thymidine Phosphorylase Gene Mutations in MNGIE, A Human Mitochondrial Disorder,” [cited by applicant]
Ostergaard, E., et al., “Mitochondrial Encephalomyopathy With Elevated Methylmalonic Acid is Caused by SUCLA2 Mutations,” [cited by applicant]
Paradas, C., et al., “TK2 Mutation Presenting as Indolent Myopathy,” [cited by applicant]
Ronchi, D., et al., “Next-Generation Sequencing Reveals DGUOK Mutations in Adult Patients With Mitochondrial DNA Multiple Deletions,” [cited by applicant]
Saada, A., et al, “Mutant Mitochondrial Thymidine Kinase in Mitochondrial DNA Depletion Myopathy,” [cited by applicant]
Saada, A., et al., “Mitochondrial Deoxyribonucleoside Triphosphate Pools in Thymidine Kinase 2 Deficiency,” [cited by applicant]
Sarzi, E., et al., “Twinkle Helicase (PEO1) Gene Mutation Causes Mitochondrial DNA Depletion,” [cited by applicant]
Spelbrink, J.N., et al., “Human Mitochondrial DNA Deletions Associated With Mutations in the Gene Encoding Twinkle, a Phage T7 Gene 4-Like Protein Localized in Mitochondria,” [cited by applicant]
Spinazzola, A., et al., “MPV17 Encodes an Inner Mitochondrial Membrane Protein and is Mutated in Infantile Hepatic Mitochondrial DNA Depletion,” [cited by applicant]
Tyynismaa, H., et al., “A Heterozygous Truncating Mutation in RRM2B Causes Autosomal-dominant Progressive External Ophthalmoplegia With Multiple mtDNA Deletions,” [cited by applicant]
Tyynismaa, H., et al., “Thymidine Kinase 2 Mutations in Autosomal Recessive Progressive External Ophthalmoplegia With Multiple Mitochondrial DNA Deletions,” [cited by applicant]